CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin
Condition(s):SarcomaLast Updated:August 19, 2019Unknown status
Hide Studies Not Open or Pending
Condition(s):SarcomaLast Updated:August 19, 2019Unknown status
Condition(s):Systemic Lupus Erythematosus; Systemic SclerosisLast Updated:November 29, 2023Recruiting
Condition(s):Immunocompromised Patients; Pneumocystis Pneumonia; Diagnosis; Polymerase Chain ReactionLast Updated:November 4, 2022Recruiting
Condition(s):LymphomaLast Updated:October 4, 2023Not yet recruiting
Condition(s):Multiple MyelomaLast Updated:January 2, 2024Not yet recruiting
Condition(s):Gastrointestinal Hemorrhage; Ulcer Hemorrhage; Tumor BleedingLast Updated:February 21, 2019Completed
Condition(s):Primary Aldosteronism Due to Aldosterone Producing AdenomaLast Updated:November 3, 2020Completed
Condition(s):Liver Transplant; Liver TransplantationLast Updated:September 20, 2018Completed
Condition(s):Human Papilloma VirusLast Updated:April 12, 2023Completed
Condition(s):Spinal Cord Injury (SCI)Last Updated:October 8, 2014Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.